8-K: Vistagen Announces Positive Phase 2A Results for PH284 Nasal Spray in Cancer Cachexia

Vistagen Therapeutics reports positive results from a Phase 2A study of PH284 nasal spray, showing improved subjective feelings of hunger in cancer patients with cachexia.

Summary

• Vistagen Therapeutics announced positive results from an exploratory Phase 2A study of PH284, an investigational pherine nasal spray, in patients with cancer cachexia.
• The study demonstrated that PH284 led to a higher mean subjective feeling of hunger compared to placebo.
• PH284 appeared safe and well-tolerated, with an adverse event profile similar to placebo in this patient population.
• The study involved 40 female patients diagnosed with cachexia due to terminal cancer.
• Patients received either PH284 or placebo four times daily before meals from Day 5 through Day 11.
• Prior to dinner on Day 7, PH284 subjects reported a 71% improvement in subjective feeling of hunger versus baseline, while placebo subjects reported less than 1% improvement.
• No unusual changes in body weight were observed, though there was a small gain in body weight for PH284 versus a small loss in placebo.
• The Phase 2A study was sponsored by Pherin Pharmaceuticals, now a wholly owned subsidiary of Vistagen, and conducted in Mexico City in 2005.
• Vistagen gained access to the results of this study in connection with its acquisition of Pherin in February 2023.
• Vistagen is currently evaluating the potential path forward for PH284, including an assessment of completed studies and studies they believe are necessary to support a U.S. Investigational New Drug application for potential further Phase 2 clinical development of PH284 for the treatment of cachexia.

Sentiment

Score: 7

Explanation: The document presents positive Phase 2A results for PH284, indicating potential for a new treatment in an area with unmet needs; however, it's an early-stage study, and further development is required, so the sentiment is cautiously optimistic.

Positives

• PH284 demonstrated a statistically significant improvement in subjective feelings of hunger compared to placebo.
• The drug was well-tolerated, with an adverse event profile similar to placebo.
• The study results support further development of PH284 as a potential treatment for cancer cachexia.
• Vistagen has a neuroscience pipeline with multiple pherine product candidates supported by positive Phase 2 or later clinical data.

Risks

• The study was an exploratory Phase 2A study with a small sample size (n=40).
• The study was conducted in 2005, and the data was only recently acquired by Vistagen in 2023.
• There is no guarantee that PH284 will successfully replicate past clinical trials, complete ongoing or future clinical trials, receive regulatory approval or be commercially successful.
• The company is still evaluating the path forward for PH284 and further clinical development.

Future Outlook

Vistagen is currently evaluating the potential path forward for PH284, including an assessment of completed studies and studies they believe are necessary to support a U.S. Investigational New Drug application for potential further Phase 2 clinical development of PH284 for the treatment of cachexia.

Management Comments

• 'We are highly encouraged by the potential of PH284 to improve the quality of life for those challenged by the debilitating impacts of cancer cachexia,' stated Shawn Singh, President and Chief Executive Officer of Vistagen.
• Loss of appetite from cancer and other illnesses not only negatively impacts overall health and quality of life, but can also reduce the effectiveness of critical therapies, such as chemotherapy in cancer patients.

Industry Context

Cachexia is a significant unmet medical need, affecting a large percentage of advanced cancer patients and contributing to a substantial number of cancer deaths; the current lack of effective medical interventions highlights the potential market for PH284 if further development is successful.

Comparison to Industry Standards

• Currently, there are no FDA-approved drugs specifically for cancer cachexia, so PH284, if approved, could be a first-in-class treatment.
• Companies like Helsinn Healthcare and Esanex (acquired by Aeterna Zentaris) have previously developed drugs targeting cancer cachexia, but none have achieved widespread success due to limited efficacy or side effects.
• The 71% improvement in SFH reported in the PH284 study is a promising signal compared to the modest benefits seen with other appetite stimulants used off-label for cachexia.

Stakeholder Impact

• Positive results could benefit cancer patients suffering from cachexia by improving their appetite and quality of life.
• Successful development and commercialization of PH284 could create value for Vistagen's shareholders.
• The study results may encourage further investment in Vistagen's neuroscience pipeline.

Next Steps

• Vistagen will assess completed studies and determine the necessary steps to support a U.S. Investigational New Drug application for potential further Phase 2 clinical development of PH284.

Key Dates